These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17971101)

  • 21. Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss.
    Choi HH; Gray PB; Storer TW; Calof OM; Woodhouse L; Singh AB; Padero C; Mac RP; Sinha-Hikim I; Shen R; Dzekov J; Dzekov C; Kushnir MM; Rockwood AL; Meikle AW; Lee ML; Hays RD; Bhasin S
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1531-41. PubMed ID: 15613414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of hormone deficiency, androgen therapy and calcium supplementation on bone mineral density in female transsexuals.
    Goh HH; Ratnam SS
    Maturitas; 1997 Jan; 26(1):45-52. PubMed ID: 9032746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals.
    Jacobeit JW; Gooren LJ; Schulte HM
    J Sex Med; 2007 Sep; 4(5):1479-84. PubMed ID: 17635694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.
    Basaria S; Collins L; Dillon EL; Orwoll K; Storer TW; Miciek R; Ulloor J; Zhang A; Eder R; Zientek H; Gordon G; Kazmi S; Sheffield-Moore M; Bhasin S
    J Gerontol A Biol Sci Med Sci; 2013 Jan; 68(1):87-95. PubMed ID: 22459616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and future testosterone delivery systems for treatment of the hypogonadal male.
    Pfeil E; Dobs AS
    Expert Opin Drug Deliv; 2008 Apr; 5(4):471-81. PubMed ID: 18426387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with percutanous testosterone gel in postmenopausal women with decreased libido--effects on sexuality and psychological general well-being.
    Nathorst-Böös J; Flöter A; Jarkander-Rolff M; Carlström K; Schoultz Bv
    Maturitas; 2006 Jan; 53(1):11-8. PubMed ID: 16183220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals.
    Giltay EJ; Toorians AW; Sarabdjitsingh AR; de Vries NA; Gooren LJ
    J Endocrinol; 2004 Jan; 180(1):107-12. PubMed ID: 14709149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of methyltestosterone postmenopausal therapy on plasma lipids, inflammatory factors, glucose metabolism and visceral fat: a randomized study.
    Leão LM; Duarte MP; Silva DM; Bahia PR; Coeli CM; de Farias ML
    Eur J Endocrinol; 2006 Jan; 154(1):131-9. PubMed ID: 16382002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder.
    Kurahashi H; Watanabe M; Sugimoto M; Ariyoshi Y; Mahmood S; Araki M; Ishii K; Nasu Y; Nagai A; Kumon H
    Endocr J; 2013; 60(12):1321-7. PubMed ID: 24047564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men.
    Allan CA; Strauss BJ; Burger HG; Forbes EA; McLachlan RI
    J Clin Endocrinol Metab; 2008 Jan; 93(1):139-46. PubMed ID: 17940111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgens and cardiovascular disease in postmenopausal women: a systematic review.
    Spoletini I; Vitale C; Pelliccia F; Fossati C; Rosano GM
    Climacteric; 2014 Dec; 17(6):625-34. PubMed ID: 24559253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study.
    Miller KK; Biller BM; Beauregard C; Lipman JG; Jones J; Schoenfeld D; Sherman JC; Swearingen B; Loeffler J; Klibanski A
    J Clin Endocrinol Metab; 2006 May; 91(5):1683-90. PubMed ID: 16478814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocrine aspects of ageing in the male.
    Gooren LJ
    Mol Cell Endocrinol; 1998 Oct; 145(1-2):153-9. PubMed ID: 9922112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased arterial stiffness in female-to-male transsexuals treated with androgen.
    Emi Y; Adachi M; Sasaki A; Nakamura Y; Nakatsuka M
    J Obstet Gynaecol Res; 2008 Oct; 34(5):890-7. PubMed ID: 18834347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
    Swerdloff RS; Wang C
    Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.
    Cardaci TD; Machek SB; Wilburn DT; Heileson JL; Harris DR; Cintineo HP; Willoughby DS
    Exp Physiol; 2022 Dec; 107(12):1467-1476. PubMed ID: 36303408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
    Mulligan K; Zackin R; Von Roenn JH; Chesney MA; Egorin MJ; Sattler FR; Benson CA; Liu T; Umbleja T; Shriver S; Auchus RJ; Schambelan M;
    J Clin Endocrinol Metab; 2007 Feb; 92(2):563-70. PubMed ID: 17090640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity.
    Bhasin S; Parker RA; Sattler F; Haubrich R; Alston B; Umbleja T; Shikuma CM;
    J Clin Endocrinol Metab; 2007 Mar; 92(3):1049-57. PubMed ID: 17164307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testosterone in older men after the Institute of Medicine Report: where do we go from here?
    Harman SM
    Climacteric; 2005 Jun; 8(2):124-35. PubMed ID: 16096168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of visceral obesity and androgens on bone: trenbolone protects against loss of femoral bone mineral density and structural strength in viscerally obese and testosterone-deficient male rats.
    Donner DG; Elliott GE; Beck BR; Forwood MR; Du Toit EF
    Osteoporos Int; 2016 Mar; 27(3):1073-1082. PubMed ID: 26438310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.